Hillsdale Investment Management’s Emergent Biosolutions EBS Stock Holding History

Hillsdale Investment Management’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-36,200	Closed	-$2.28M	–	578
2021 Q2	$2.28M	Hold	36,200	–	–	0.18%	154
2021 Q1	$3.36M	Sell	36,200 -8,800	-20%	-$901K	0.28%	128
2020 Q4	$4.03M	Sell	45,000 -300	-0.7%	-$27.5K	0.38%	82
2020 Q3	$4.68M	Sell	45,300 -12,800	-22%	-$1.38M	0.46%	44
2020 Q2	$4.59M	Sell	58,100 -2,700	-4%	-$201K	0.42%	48
2020 Q1	$3.52M	Buy	+60,800	New	+$3.5M	0.42%	54
2018 Q2	–	Sell	-29,900	Closed	-$1.57M	–	509
2018 Q1	$1.57M	Hold	29,900	–	–	0.22%	63
2017 Q4	$1.39M	Buy	+29,900	New	+$1.26M	0.22%	79

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Hillsdale Investment Management's EBS Position: Q3 2021 in Review

Hillsdale Investment Management sold out of Emergent Biosolutions (EBS) in Q3 2021, closing a stake of 36,200 shares — an estimated $2.28M sold.

Hillsdale Investment Management first reported a position in EBS in Q4 2017 and held it in 8 quarters. The position peaked at $4.68M in Q3 2020. 277 funds tracked by Wall St. Rank hold EBS as of Q3 2021.

Hillsdale Investment Management reported no remaining Emergent Biosolutions position as of Q3 2021 after selling out during the quarter.
Hillsdale Investment Management sold 36,200 Emergent Biosolutions shares in Q3 2021, an estimated $2.28M.
Hillsdale Investment Management first reported a position in Emergent Biosolutions in Q4 2017 and held it in 8 quarters.
Hillsdale Investment Management's Emergent Biosolutions position peaked at $4.68M in Q3 2020.
277 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2021.

Based on Hillsdale Investment Management's 13F filing for Q3 2021, filed 21 Oct 2021.